Corient Private Wealth LP Decreases Stake in Becton, Dickinson and Company $BDX

Key Points

• Corient Private Wealth LP cut its Becton, Dickinson and Company stake by 9.4% in the second quarter, selling 7,308 shares and retaining 70,198 shares valued at approximately $10.6 million. Institutional investors and hedge funds collectively own 86.97% of BDX.
• Analyst sentiment is mixed, with eight Buy, eight Hold and one Sell rating; the overall consensus is Hold with a target price of $187.67. BDX shares recently opened at $182, near their 52-week high of $193.07.
• BDX exceeded quarterly expectations, reporting $3.23 in earnings per share and $4.98 billion in revenue, while revenue rose 5.4% year over year. The company declared a $1.05 quarterly dividend, equal to a 2.3% annualized yield.

Corient Private Wealth LP lessened its position in shares of Becton, Dickinson and Company (NYSE:BDX - Free Report) by 9.4% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 70,198 shares of the medical instruments supplier's stock after selling 7,308 shares during the period. Corient Private Wealth LP's holdings in Becton, Dickinson and Company were worth $10,623,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of the company. Amundi boosted its holdings in shares of Becton, Dickinson and Company by 11.4% in the 2nd quarter. Amundi now owns 1,816,703 shares of the medical instruments supplier's stock valued at $274,922,000 after buying an additional 186,541 shares in the last quarter. First Eagle Investment Management LLC grew its holdings in shares of Becton, Dickinson and Company by 15.8% during the second quarter. First Eagle Investment Management LLC now owns 13,815,335 shares of the medical instruments supplier's stock worth $2,090,675,000 after purchasing an additional 1,887,224 shares during the last quarter. Studio Investment Management LLC increased its position in shares of Becton, Dickinson and Company by 11.2% during the second quarter. Studio Investment Management LLC now owns 11,872 shares of the medical instruments supplier's stock worth $1,797,000 after purchasing an additional 1,193 shares in the last quarter. Wedmont Private Capital acquired a new stake in shares of Becton, Dickinson and Company during the second quarter worth about $206,000. Finally, Kintra Wealth LLC purchased a new stake in shares of Becton, Dickinson and Company in the 2nd quarter valued at about $384,000. 86.97% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

BDX has been the topic of a number of research reports. The Goldman Sachs Group dropped their price target on Becton, Dickinson and Company from $156.00 to $150.00 and set a "neutral" rating on the stock in a research note on Wednesday, May 27th. Stifel Nicolaus set a $195.00 target price on shares of Becton, Dickinson and Company in a research report on Friday, August 7th. Bank of America upped their target price on shares of Becton, Dickinson and Company from $185.00 to $200.00 and gave the company a "neutral" rating in a report on Monday, August 31st. TD Cowen increased their target price on shares of Becton, Dickinson and Company from $163.00 to $182.00 and gave the stock a "hold" rating in a research note on Wednesday, August 5th. Finally, Weiss Ratings reissued a "sell (d+)" rating on shares of Becton, Dickinson and Company in a report on Friday, August 7th. Eight investment analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock has an average rating of "Hold" and a consensus target price of $187.67.

Becton, Dickinson and Company Price Performance

Shares of NYSE:BDX opened at $182.00 on Thursday. The company has a quick ratio of 0.51, a current ratio of 0.87 and a debt-to-equity ratio of 0.55. The company has a market cap of $50.15 billion, a P/E ratio of 54.82, a PEG ratio of 13.10 and a beta of 0.21. Becton, Dickinson and Company has a 52 week low of $127.59 and a 52 week high of $193.07. The company has a 50-day moving average price of $174.28 and a 200 day moving average price of $160.56.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last released its earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.14 by $0.09. The company had revenue of $4.98 billion for the quarter, compared to analysts' expectations of $4.89 billion. Becton, Dickinson and Company had a return on equity of 14.79% and a net margin of 4.52%.The firm's quarterly revenue was up 5.4% on a year-over-year basis. During the same quarter in the previous year, the firm posted $3.68 EPS. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. Research analysts predict that Becton, Dickinson and Company will post 12.67 earnings per share for the current year.

Becton, Dickinson and Company Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, September 30th. Stockholders of record on Wednesday, September 9th will be issued a $1.05 dividend. This represents a $4.20 dividend on an annualized basis and a dividend yield of 2.3%. The ex-dividend date is Wednesday, September 9th. Becton, Dickinson and Company's dividend payout ratio (DPR) is currently 126.51%.

Insider Activity at Becton, Dickinson and Company

In other news, EVP Michael Feld sold 165 shares of the business's stock in a transaction that occurred on Wednesday, August 26th. The stock was sold at an average price of $188.49, for a total transaction of $31,100.85. Following the sale, the executive vice president owned 19,720 shares of the company's stock, valued at $3,717,022.80. The trade was a 0.83% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Thomas E. Polen, Jr. sold 4,152 shares of the company's stock in a transaction that occurred on Thursday, August 13th. The stock was sold at an average price of $185.00, for a total value of $768,120.00. Following the completion of the sale, the chief executive officer owned 110,163 shares in the company, valued at approximately $20,380,155. This represents a 3.63% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 8,005 shares of company stock worth $1,423,580 over the last three months. 0.40% of the stock is currently owned by company insiders.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company, commonly known as BD, is a global medical technology company that develops, manufactures and sells products used by healthcare providers, researchers and pharmaceutical companies. Founded in 1897 by Maxwell Becton and Fairleigh Dickinson, the company is headquartered in Franklin Lakes, New Jersey.

BD's products support medication delivery, infection prevention, diagnostics and surgical care. Its portfolio includes needles, syringes, injection devices, infusion products, medication-management systems, specimen-collection products, laboratory instruments and diagnostic technologies.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.